Prevention and management of occupational exposures to human immunodeficiency virus (HIV)

Mount Sinai Journal of Medicine

Volumn 73, Issue 6, 2006, Pages 852-856

  Calfee, David P ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Needlestick injury; Occupational exposure; Post exposure prophylaxis; Precautions

Indexed keywords

TENOFOVIR; ZIDOVUDINE;

ARTICLE; BLOOD; BODY FLUID; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION RISK; NONHUMAN; OCCUPATIONAL EXPOSURE; PROPHYLAXIS; PROTECTIVE EQUIPMENT; RISK REDUCTION; VIRUS TRANSMISSION;

ADULT; BLOOD-BORNE PATHOGENS; CHEMOPREVENTION; DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; HEALTH PERSONNEL; HIV INFECTIONS; HUMANS; INFECTION CONTROL; MIDDLE AGED; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 33751103402     PISSN: 00272507     EISSN: 00272507     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Do A, Ciesielski C, Metler R, et al. Occupationally acquired human immunodeficiency virus (HIV) infection: national case surveillance data during 20 years of the HIV epidemic in the United States. Infect Control Hosp Epidemiol 2003; 24(2):86-96.
2. Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001; 50(RR-11):1-42.
3. International Health Care Worker Safety Center. Annual number of occupational percutaneous injuries and mucocutaneous exposures to blood or potentially infective biological substances. http://www.healthsystem.virginia.edu/internet/epinet/estimates.cfm [Accessed May 12, 2006]
4. Perry J, Parker G, Jagger J. EPINet report: 2003 percutaneous injury rates. Advances in Exposure Prevention 2005; 7(4):42-45.
5. Dement J, Epling C, Ostbye T, et al. Blood and body fluid exposure risks among health care workers: results from the Duke Health and Safety Surveillance System. Am J Ind Med 2004; 46:637-648.
6. Trapé-Cardoso M, Schenck P. Reducing percutaneous injuries at an academic health center: a 5-year review. Am J Infect Control 2004; 32:301-305.
7. Bell D. Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am J Med 1997; 102(5B):9-15.
8. Cardo D, Culver D, Ciesielski C, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. New Engl J Med 1997; 337(21):1485-1490.
9. Landrum M, Wilson C, Perri L, Han et al. Usefulness of a rapid human immunodeficiency virus-1 antibody test for the management of occupational exposure to blood and body fluid. Infect Control Hosp Epidemiol 2005; 26(9):768-774.
10. Seibert C. Stuck. Ann Intern Med 2003; 138(9):765-766.
11. Meienberg F, Bucher H, Sponagel L, et al. Anxiety in health care workers after exposure to potentially HIV-contaminated blood or body fluids. Swiss Med Wkly 2002; 132(2324):321-324.
12. Garner J, Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol 1996; 17(1):54-80.
13. Occupational Safety and Health Administration. Bloodborne pathogens standard. 29 CFR 1910 1030 2001.
14. Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR 2005; 54(RR-9):1-17.
15. Glynn M, Rhodes P. Estimated HIV prevalence in the United States at the end of 2003. Natl HIV Prev Conf 2005.
16. Puro V, Francisci D, Sighinolfi L, et al. Benefits of a rapid HIV test for evaluation of the source patient after occupational exposure of healthcare workers. J Hosp Infect 2004; 57:179-182.
17. Greub G, Maziéro A, Bürgisser P, et al. Spare post-exposure prophylaxis with round-the-clock HIV testing of the source patient. AIDS 2001; 15(18):2451-2452.
18. Wade N, Birkhead G, Warren B, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. New Engl J Med 1998; 339(20):1409-1414.
19. Tsai C, Follis K, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 1995; 270(5239):1197-1199.
20. Tsai C, Emau P, Follis Y., et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIV mne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72(5):4265-4273.
21. New York State Department of Health AIDS Institute. HIV prophylaxis following occupational exposure. 2004.
22. Braitstein P, Chan K, Beardsell A, et al. Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting. J Acquir Immune Defic Syndr 2002; 29(5):547-548.
23. Lee L, Henderson D. Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV. Drug Safety 2001; 24(8):587-597.
24. Puro V, De Carli G, Orchi N, et al. Short-term adverse effects from and discontinuation of antiretroviral post-exposure prophylaxis. J Biol Regul Homeost Agents 2001; 15(3):238-242.
25. Wang S, Panlilio A, Doi P, et al. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV Postexposure Prophylaxis Registry. Infect Control Hosp Epidemiol 2000; 21:780-785.